FLIPI24: A Modern Prognostic Model and Clinical Trial
Enrichment Tool for Newly Diagnosed Follicular Lymphoma

J 2026

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

MAURER, Matthew J; Vit K PROCHAZKA; Tarec Christoffer EL-GALALY; Christopher R FLOWERS; Diego VILLA et al.

Základní údaje

Originální název

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Autoři

MAURER, Matthew J; Vit K PROCHAZKA; Tarec Christoffer EL-GALALY; Christopher R FLOWERS; Diego VILLA; Emmanuel BACHY; Elliot J CAHN; Marguerite FOURNIER; Melissa C LARSON; Caroline E DIETRICH; Lasse Hjort JAKOBSEN; Herve GHESQUIERES; Robert KRIDEL; Maher K GANDHI; Chan Y CHEAH; Eliza A HAWKES; John F SEYMOUR; Ciara L FREEMAN; Michael R CLAUSEN; Bjorn E WAHLIN; Jonathan W FRIEDBERG; Carla CASULO; Thomas M HABERMANN; Yucai WANG; Loretta J NASTOUPIL; De Nully Brown PETER; David BELADA; Andrea JANÍKOVÁ; Heidi MOCIKOVA; Tomas FURST; Pierre FEUGIER; Herve TILLY; Corinne HAIOUN; Andrew J DAVIES; Guillaume CARTRON; Richard BURACK; Dai CHIHARA; Martin PETER; Jonathon B COHEN; Izidore S LOSSOS; Brad S KAHL; Laurie H SEHN; Karin E SMEDBY; Gilles SALLES; Marek TRNENY; Brian K LINK; Franck MORSCHHAUSER a James R CERHAN

Vydání

Journal of clinical oncology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2026, 0732-183X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 41.900 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

follicular lymphoma; FLIPI24; prognostic model; clinical trial enrichment; newly diagnosed patients

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 4. 2026 12:44, Mgr. Tereza Miškechová

Anotace

V originále

PURPOSEAlthough most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed.METHODSThe FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074).RESULTSThe FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL.CONCLUSIONThe FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.

Citovat

@article{2565460,
   author = {Maurer, Matthew J and Prochazka, Vit K and ElandGalaly, Tarec Christoffer and Flowers, Christopher R and Villa, Diego and Bachy, Emmanuel and Cahn, Elliot J and Fournier, Marguerite and Larson, Melissa C and Dietrich, Caroline E and Jakobsen, Lasse Hjort and Ghesquieres, Herve and Kridel, Robert and Gandhi, Maher K and Cheah, Chan Y and Hawkes, Eliza A and Seymour, John F and Freeman, Ciara L and Clausen, Michael R and Wahlin, Bjorn E and Friedberg, Jonathan W and Casulo, Carla and Habermann, Thomas M and Wang, Yucai and Nastoupil, Loretta J and Peter, De Nully Brown and Belada, David and Janíková, Andrea and Mocikova, Heidi and Furst, Tomas and Feugier, Pierre and Tilly, Herve and Haioun, Corinne and Davies, Andrew J and Cartron, Guillaume and Burack, Richard and Chihara, Dai and Peter, Martin and Cohen, Jonathon B and Lossos, Izidore S and Kahl, Brad S and Sehn, Laurie H and Smedby, Karin E and Salles, Gilles and Trneny, Marek and Link, Brian K and Morschhauser, Franck and Cerhan, James R},
   article_location = {PHILADELPHIA},
   article_number = {2},
   doi = {https://doi.org/10.1200/JCO-25-00892},
   keywords = {follicular lymphoma; FLIPI24; prognostic model; clinical trial enrichment; newly diagnosed patients},
   language = {eng},
   issn = {0732-183X},
   journal = {Journal of clinical oncology},
   title = {FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma},
   url = {https://ascopubs.org/doi/10.1200/JCO-25-00892},
   volume = {44},
   year = {2026}
}

TY  - JOUR
ID  - 2565460
AU  - Maurer, Matthew J - Prochazka, Vit K - El-Galaly, Tarec Christoffer - Flowers, Christopher R - Villa, Diego - Bachy, Emmanuel - Cahn, Elliot J - Fournier, Marguerite - Larson, Melissa C - Dietrich, Caroline E - Jakobsen, Lasse Hjort - Ghesquieres, Herve - Kridel, Robert - Gandhi, Maher K - Cheah, Chan Y - Hawkes, Eliza A - Seymour, John F - Freeman, Ciara L - Clausen, Michael R - Wahlin, Bjorn E - Friedberg, Jonathan W - Casulo, Carla - Habermann, Thomas M - Wang, Yucai - Nastoupil, Loretta J - Peter, De Nully Brown - Belada, David - Janíková, Andrea - Mocikova, Heidi - Furst, Tomas - Feugier, Pierre - Tilly, Herve - Haioun, Corinne - Davies, Andrew J - Cartron, Guillaume - Burack, Richard - Chihara, Dai - Peter, Martin - Cohen, Jonathon B - Lossos, Izidore S - Kahl, Brad S - Sehn, Laurie H - Smedby, Karin E - Salles, Gilles - Trneny, Marek - Link, Brian K - Morschhauser, Franck - Cerhan, James R
PY  - 2026
TI  - FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
JF  - Journal of clinical oncology
VL  - 44
IS  - 2
SP  - 1-15
EP  - 1-15
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 0732183X
KW  - follicular lymphoma
KW  - FLIPI24
KW  - prognostic model
KW  - clinical trial enrichment
KW  - newly diagnosed patients
UR  - https://ascopubs.org/doi/10.1200/JCO-25-00892
N2  - PURPOSEAlthough most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed.METHODSThe FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074).RESULTSThe FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL.CONCLUSIONThe FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.
ER  -

Přehled o publikaci